3 hours Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC WainwrightMarketBeat
HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday.
XHC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday.
X